Tesamorelin Before and After: What Results Really Look Like

Most people search tesamorelin before and after hoping to see a flat-stomach transformation photo. The honest answer is that tesamorelin does not usually create a dramatic mirror change. It works on a specific kind of fat, and it barely moves the scale.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. In plain English, it tells your body to make a bit more of its own growth hormone. That extra signal mostly burns visceral fat, the deep belly fat that wraps around your organs.

So the real before and after shows up as a smaller waist, not a lighter scale. Changes are slow and steady. Most people see little at one month and a clearer difference around 8 to 12 weeks. For dose and reconstitution math, use the tesamorelin protocol on Peptide Dosing Protocols and our peptide calculator.

When people compare tesamorelin before and after, the changes that matter are about body shape, not body weight. Here is what tends to move and what usually does not.

This is why some people feel like "nothing is happening." The scale is not moving, so they assume the peptide failed. But their belt may already be looser. With tesamorelin, the belt is the better judge than the scale.

Results build slowly. The trials measured the big changes at 26 weeks, so patience matters. Here is a rough timeline people describe.

One month is early. Many people see almost nothing visible yet. Some notice better sleep or slightly less bloating. Real waist and body composition changes usually need longer, so do not judge results at the 4-week mark.

Belly fat comes in two main types. Knowing the difference explains why tesamorelin photos can be confusing.

Tesamorelin mostly targets visceral fat. In the main Phase III trial, it cut visceral fat by about 15% over 26 weeks while the placebo group gained a little. But it changed the pinchable layer much less.

That is why a tape measure at the belly button beats the bathroom scale, and often beats the mirror too. If your waist is shrinking but your weight is flat, tesamorelin may be doing exactly what it does in the data.

The Phase III trials included both men and women, and the visceral-fat effect showed up in both. What people search for tends to differ by sex.

For both, the rule is the same: judge by the tape measure and side-profile photos, not the scale. Big swings in the first month are unlikely for anyone.

A lot of people compare or stack tesamorelin with ipamorelin. They work on the same growth hormone system but from different angles.

Here is the honest part: there is no large human trial of the tesamorelin + ipamorelin combo. The strong before and after data is for tesamorelin alone, in HIV patients. Stack results online are anecdotal. For protocol structure, see the ipamorelin protocol and the CJC-1295 + ipamorelin GH pulse stack.

Two people can run the same peptide and get very different before and after photos. These factors explain most of the gap.

If you also want a fat-loss overview beyond GH peptides, see our best peptides for fat loss guide.

Tesamorelin has stronger before and after data than most peptides, because it is FDA-approved and was tested in real trials. The catch is who it was tested on.

In a 2007 New England Journal of Medicine Phase III trial of about 412 patients, 2 mg of tesamorelin a day cut visceral fat by roughly 15% over 26 weeks, while the placebo group gained a little. A pooled analysis of two Phase III trials (about 806 patients) confirmed it. I read the original 2007 paper to check the 15% figure myself before writing this.

Two more things from the data matter for before and after. First, the effect is selective: visceral fat fell, but pinchable fat and total weight barely changed. Second, when people stopped, the fat came back within about 26 weeks. The change is not permanent on its own.

On status: tesamorelin (brand Egrifta) was first FDA-approved in November 2010. The current branded form, Egrifta WR, was FDA-approved in March 2025 and became available in September 2025. It is approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and it is labeled weight-neutral, not a weight-loss drug.

Reddit and forum reports are not proof, but they show what people consistently talk about. Read them as shared experience, not data.

The pattern matches the trial data on one key point: people who track waist size, not scale weight, are far happier with their tesamorelin before and after.